OWC Pharmaceutical Research OWCP · USD

Its shares trade under the ticker OWCP. It has been listed since 20 August 2008. In the fiscal year to 31 December 2016, it reported revenue of $50,000 and a net loss of $2.3m. At that date it held total assets of $496,768 and shareholders' equity of $100,988.

OWC Pharmaceutical Research Corp. engages in the research and development of cannabis-based medical products for the treatment of myeloma and psoriasis. The firm is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The firm also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Zvi TurnerChief Executive Officer, since 2020
• Mr. Alon SinaiChief Operating Officer$94,000
• Dr. Oron Yacoby ZeeviChief Scientific Officer
• Dr. Yehuda BaruchChief Medical and Regulatory Officer$112,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.